1-20 of 219
John P. Leonard
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Clinical Trials & Observations
Mitchell R. Smith, Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir S. Parekh, David T. Yang, Eric D. Hsi, Thomas Witzig, Sandeep Dave, David Scott, Curtis Hanson, Lale Kostakoglu Shields, Nizar Abdel-Samad, Carla Casulo, Nancy L. Bartlett, Paolo F. Caimi, Tareq Al Baghdadi, Kristie A. Blum, Mark D. Romer, David J. Inwards, Rachel E. Lerner, Lynne I. Wagner, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl
Journal: Blood
Blood (2024) 144 (10): 1083–1092.
https://doi.org/10.1182/blood.2024023962
Published: 2024
Includes: Supplemental data
Journal Articles

Improvements in Overall Survival in Older Patients with Mantle Cell Lymphoma Are Driven By Improvements across Multiple Lines of Therapy

Danny Luan, Neela Easwar, Zhengming Chen, Brian K. Link, Yucai Wang, Matthew J. Maurer, Brad S. Kahl, Laura Pinheiro, John P. Leonard, Peter Martin
Journal: Blood
Blood (2023) 142 (Supplement 1): 1664.
https://doi.org/10.1182/blood-2023-184807
Published: 2023
Journal Articles

Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

Maurizio Di Liberto, Yang Hu, Xiangao Huang, Giorgio Inghirami, Kevin Wang, Christina Lee, Kami J. Maddocks, Kristie A. Blum, Jia Ruan, John P. Leonard, Nancy L. Bartlett, Peter Martin, Olivier Elemento, Selina Chen-Kiang
Journal: Blood
Blood (2023) 142 (Supplement 1): 50.
https://doi.org/10.1182/blood-2023-190308
Published: 2023
Journal Articles

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Narendranath Epperla, Jeffrey M. Switchenko, Susan M. Geyer, Veronika Bachanova, Stefan K. Barta, Alexey Danilov, Natalie S. Grover, Reem Karmali, Brian T. Hill, Nilanjan Ghosh, Timothy S. Fenske, Peter Martin, Brad S. Kahl, Christopher R. Flowers, Brian K. Link, Eric D. Hsi, Kami J. Maddocks, Kristie A. Blum, Thomas M. Habermann, Matthew J. Maurer, Lawrence David Kaplan, Nancy L. Bartlett, John P. Leonard, Jonathon B. Cohen
Journal: Blood
Blood (2023) 142 (Supplement 1): 380.
https://doi.org/10.1182/blood-2023-189505
Published: 2023
Journal Articles

Rates of Ibrutinib Uptake Among Black Patients with Lymphoma in SEER-Medicare Increased over Time

Danny Luan, Rahma Ibrahim, Zhengming Chen, John P. Leonard, Laura Pinheiro, Peter Martin
Journal: Blood
Blood (2023) 142 (Supplement 1): 7372.
https://doi.org/10.1182/blood-2023-190900
Published: 2023
Journal Articles

Ilyad: A Phase III Double Blind, Randomized Trial Evaluating Vitamin D (Cholecalciferol) in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy

Jonathan W. Friedberg, Michael T. Brady, Strawderman Myla, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, Barbara L. Averill, Brian K. Link, Paul M. Barr, John P. Leonard, John M. Ashton, Derick R Peterson, Loretta J. Nastoupil
Journal: Blood
Blood (2023) 142 (Supplement 1): 606.
https://doi.org/10.1182/blood-2023-178088
Published: 2023
Journal Articles

Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)

John N. Allan, Daniel Helbig, Erin Mulvey, Sarah Nazir, Sandra Stewart, Melissa L. Lapinta, Sarah C. Rutherford, Jia Ruan, John P. Leonard, Peter Martin, Richard R. Furman
Journal: Blood
Blood (2023) 142 (Supplement 1): 3285.
https://doi.org/10.1182/blood-2023-174465
Published: 2023
Journal Articles

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Charalambos Andreadis, Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Susan M. Geyer, Patrick J. Stiff, Brian T. Hill, Mitchell Horwitz, Farhad Khimani, Richard F. Little, Shira N. Dinner, Jonathan W. Friedberg, Brad S. Kahl, Miguel-Angel Perales, Steven M. Devine, John P. Leonard, Nancy L. Bartlett
Journal: Blood
Blood (2023) 142 (Supplement 1): 437.
https://doi.org/10.1182/blood-2023-173742
Published: 2023
Journal Articles

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Seda S. Tolu, Caitlin Gribbin, Madhav R Seshadri, Zhengming Chen, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Adrienne A. Phillips, Tsiporah B. Shore, Peter Martin, John P. Leonard, Barbara Pro, Jennifer E. Amengual, Jia Ruan
Journal: Blood
Blood (2023) 142 (Supplement 1): 1698.
https://doi.org/10.1182/blood-2023-178231
Published: 2023
Journal Articles

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Sarah C. Rutherford, Hongli Li, Alex F. Herrera, Michael Leblanc, Sairah Ahmed, Kelly L. Davison, Carla Casulo, Nancy L. Bartlett, Joseph M Tuscano, Brian Hess, Pallawi Torka, Pankaj Kumar, Ryan W Jacobs, Joo Y Song, Sharon M. Castellino, Brad S. Kahl, John P. Leonard, Sonali M. Smith, Jonathan W. Friedberg, Andrew M Evens
Journal: Blood
Blood (2023) 142 (Supplement 1): 181.
https://doi.org/10.1182/blood-2023-180114
Published: 2023
Journal Articles

An Externally Controlled Trial to Indirectly Compare Tazemetostat Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab after at Least One Prior Systemic Therapy in Patients with Refractory and Relapsed Follicular Lymphoma

Loretta J. Nastoupil, Gilles Salles, John P. Leonard, Frank Morschhauser, Kylee Jordan Veazey, Valerie Perrot, Vitalii Doban, Marion Bonnet, Alexandra Z. Sosinsky, Aaron Crowley, Camryn Lieb, Zhengfan Wang, Bret Zeldow, Joanna Harton, Shu Wang, Tamer Garawin
Journal: Blood
Blood (2023) 142 (Supplement 1): 4410.
https://doi.org/10.1182/blood-2023-181807
Published: 2023
Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up

Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David J Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Yingxue Chen, Jade Chen, Rajat Bannerji, Apoorva Kapopara, Attila Szanto, Franck Morschhauser
Journal: Blood
Blood (2023) 142 (Supplement 1): 3035.
https://doi.org/10.1182/blood-2023-179910
Published: 2023
Journal Articles

Engaging Underrepresented Patients in Hematology Clinical Trials through the LLS Impact (Influential Medicine Providing Access to Clinical Trials) Research Grant: A Multi-Institutional Effort

Eden Ayele Biltibo, Zachary Copeland, Erik Nelson, Nina Logan, Kellie Jack, Jamie Johnston, Veronica Leautaud, Lammers Philip, Salil Goorha, Brion Randolph, Jonathon B. Cohen, Melissa Kives, Michael Yaffe, Lee M. Greenberger, Christopher R. Flowers, Tanya Siddiqi, Clayton Smith, Erica Phillips, John P. Leonard, Grzegorz S. Nowakowski, Michael R. Savona
Journal: Blood
Blood (2023) 142 (Supplement 1): 7237.
https://doi.org/10.1182/blood-2023-191067
Published: 2023
Journal Articles

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Clinical Trials & Observations
Jia Ruan, Alison Moskowitz, Neha Mehta-Shah, Lubomir Sokol, Zhengming Chen, Nikita Kotlov, Grigorii Nos, Maria Sorokina, Vladislav Maksimov, Andrea Sboner, Michael Sigouros, Koen van Besien, Steven Horwitz, Sarah C. Rutherford, Erin Mulvey, Maria V. Revuelta, Jenny Xiang, Alicia Alonso, Ari Melnick, Olivier Elemento, Giorgio Inghirami, John P. Leonard, Leandro Cerchietti, Peter Martin
Journal: Blood
Blood (2023) 141 (18): 2194–2205.
https://doi.org/10.1182/blood.2022018254
Published: 2023
Includes: Supplemental data
Journal Articles

Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study

Reem Karmali, Daniel J. Landsburg, Jason Westin, John P. Leonard, Emil T. Kuriakose, Bradley James Sumrow, Susheela Carroll, Katherine Albert, Lalith Akella, Leo I. Gordon
Journal: Blood
Blood (2022) 140 (Supplement 1): 12125–12126.
https://doi.org/10.1182/blood-2022-165502
Published: 2022
Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Connie Lee Batlevi, Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Manu Sondhi, Yingxue Chen, Pamela L. Slatcher, Richard Lin, Attila Szanto, Sara Abbadi, Franck Morschhauser
Journal: Blood
Blood (2022) 140 (Supplement 1): 2296–2298.
https://doi.org/10.1182/blood-2022-166991
Published: 2022
Journal Articles

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Danny Luan, Chen Zhengming, Lasse Hjort Jakobsen, Matthew J. Maurer, Tarec Christoffer Christoffer El-Galaly, Loretta J. Nastoupil, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Izidore S. Lossos, Deborah M. Stephens, Thomas M. Habermann, Grzegorz S. Nowakowski, Nancy L. Bartlett, Jonathan W. Friedberg, Brad S. Kahl, John P. Leonard, Peter De Nully Brown, Karin E. Smedby, Mats Jerkeman, Peter Martin
Journal: Blood
Blood (2022) 140 (Supplement 1): 1921–1923.
https://doi.org/10.1182/blood-2022-164692
Published: 2022
Journal Articles

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Mitchell R Smith, Opeyemi Jegede, Peter Martin, Brian G. Till, Samir Parekh, David T. Yang, Lale Kostakoglu, Carla Casulo, Nancy Bartlett, Paolo F Caimi, Tareq Al Baghdadi, Kami J. Maddocks, Mark D. Romer, David J. Inwards, Rachel E. Lerner, Lynne I. Wagner, Richard Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl
Journal: Blood
Blood (2022) 140 (Supplement 1): 186–188.
https://doi.org/10.1182/blood-2022-170381
Published: 2022
Journal Articles

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Jia Ruan, John P. Leonard, Gui Zhen Chen, Zhengming Chen, John N. Allan, Sarah C. Rutherford, Brittany Hobbie, Katie Greig, Amelyn Rodriguez, Wayne Tam, David A. Bond, Bijal D. Shah, Kami J. Maddocks, Bhavneet Binder, Giorgio Inghirami, Olivier Elemento, Selina Chen-Kiang, Peter Martin
Journal: Blood
Blood (2022) 140 (Supplement 1): 175–177.
https://doi.org/10.1182/blood-2022-158656
Published: 2022
Journal Articles

Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

John P. Leonard, Marek Trneny, Fritz Offner, Jiri Mayer, Huilai Zhang, Grzegorz S. Nowakowski, Phillip Scheinberg, Argyrios Gkasiamis, Joanna Mikita-Geoffroy, Everton Rowe, John G. Gribben
Journal: Blood
Blood (2022) 140 (Supplement 1): 561–563.
https://doi.org/10.1182/blood-2022-158631
Published: 2022